Medtronic (MDT)
(Delayed Data from NYSE)
$82.84 USD
+0.08 (0.10%)
Updated May 10, 2024 04:00 PM ET
After-Market: $82.79 -0.05 (-0.06%) 7:58 PM ET
4-Sell of 5 4
B Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$82.84 USD
+0.08 (0.10%)
Updated May 10, 2024 04:00 PM ET
After-Market: $82.79 -0.05 (-0.06%) 7:58 PM ET
4-Sell of 5 4
B Value D Growth D Momentum D VGM
Zacks News
Here's How Medtronic (MDT) Is Placed Ahead of Q4 Earnings
by Moumi Mondal
Medtronic's (MDT) rapid cadence of new product approvals is a strong foundation for future growth. However, the company also navigates some macroeconomic challenges.
Apyx Medical (APYX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of -22.22% and 6.27%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
National Vision (EYE) Q1 Earnings Top Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 7.14% and 2.68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 12.25% and 0.23%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Medtronic (MDT) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
The latest trading day saw Medtronic (MDT) settling at $81.76, representing a +0.09% change from its previous close.
Medtronic PLC (MDT) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Medtronic (MDT). This makes it worthwhile to examine what the stock has in store.
Medtronic (MDT) Rises Higher Than Market: Key Facts
by Zacks Equity Research
Medtronic (MDT) closed at $80.86 in the latest trading session, marking a +1.4% move from the prior day.
Medtronic PLC (MDT) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Medtronic (MDT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Medtronic (MDT) Laps the Stock Market: Here's Why
by Zacks Equity Research
Medtronic (MDT) reachead $80.57 at the closing of the latest trading day, reflecting a +1.37% change compared to its last close.
Here's Why You Should Retain Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) due to the strength of its Neurosurgery and Cardiovascular portfolios.
The Zacks Analyst Blog Highlights Mastercard, Netflix, Coca-Cola, Berkshire Hathaway and Medtronic
by Zacks Equity Research
Mastercard, Netflix, Coca-Cola, Berkshire Hathaway and Medtronic are included in this Analyst Blog.
Medtronic (MDT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Medtronic (MDT) concluded the recent trading session at $79.35, signifying a -1.1% move from its prior day's close.
Q1 Earnings Scorecard and Analyst Reports for Mastercard, Netflix & Coca-Cola
by Sheraz Mian
Today's Research Daily features a real-time update on the Q1 earnings season and new research reports Mastercard (MA), Netflix (NFLX) and Coke (KO) and others.
Medtronic PLC (MDT) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Medtronic (MDT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Medtronic's (MDT) Sphere-360 PFA Study Outcome Favorable
by Zacks Equity Research
Medtronic's (MDT) Sphere-360 catheter is designed to simplify the atrial fibrillation process while increasing efficiency and giving long-lasting lesions.
Medtronic (MDT) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
Medtronic (MDT) reachead $82.33 at the closing of the latest trading day, reflecting a -1.75% change compared to its last close.
Medtronic (MDT) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Medtronic (MDT) stood at $83.92, denoting a -1.27% change from the preceding trading day.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Medtronic's (MDT) Newest Evolut TAVR System Gets FDA Approval
by Zacks Equity Research
Medtronic (MDT) announces the FDA approval of the newest-generation Evolut TAVR system for the treatment of symptomatic severe aortic stenosis.
National Vision (EYE) Down 4.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abbott (ABT) Expands in Canada With First Eterna SCS Use
by Zacks Equity Research
Abbott's (ABT) Eterna SCS system reduces pain without causing discomfort. It leverages the BurstDR stimulation technology.
Medtronic (MDT) Down 2.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) on the strength of the Neurosurgery and Cardiovascular and Neurosurgery portfolios.
Medtronic's (MDT) MiniMed 780G System Study Data Favorable
by Zacks Equity Research
Medtronic's (MDT) data from a recent study indicate that the MiniMed 780G system exceeds international targets for TIR and even brings patients closer to euglycemia.
The Zacks Analyst Blog Highlights Eli Lilly, The Procter & Gamble, Morgan Stanley, AT&T and Medtronic
by Zacks Equity Research
Eli Lilly, The Procter & Gamble, Morgan Stanley, AT&T and Medtronic are part of the Zacks top Analyst Blog.